Candel therapeutics reports prolonged overall survival in phase 2 clinical trial of can-2409 for advanced non-small cell lung cancer (nsclc) in patients non-responsive to immune checkpoint inhibitor (ici) treatment at 2024 asco annual meeting

Needham, mass., may 23, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced topline overall survival data from its phase 2 clinical trial of can-2409, a multimodal biological immunotherapy candidate, plus valacyclovir (prodrug), together with standard of care (soc) immune checkpoint inhibitor (ici) therapy in patients with stage iii/iv non-small cell lung cancer (nsclc) inadequately responding to ici (anti-pd-(l)1) therapy.  the data will be presented at the 2024 american society of clinical oncology (asco) annual meeting, to be held in chicago, may 31 to june 4, 2024, by charu aggarwal, md, mph, fasco, leslye m. heisler associate professor for lung cancer excellence at the perelman school of medicine, university of pennsylvania and co-principal investigator of the clinical trial.
CADL Ratings Summary
CADL Quant Ranking